CLLSA Newsletter Winter 2016

Welcome to the Winter issue of the newsletter! 

You will be pleased to know we have once again been very busy in the last few months and here are some of the is-sues we have been handling. 

As always the introduction of new treatments is never an easy job given all the financial constraints on health budgets nationwide and this time around is no exception. 

NICE says YES to Ibrutinib to treat England and Wales NHS CLL patients

CLLSA are extremely pleased by the NICE decision to approve Ibrutinib to treat NHS England and Wales chronic lymphocytic leukaemia patients.

Today’s Final Appraisal Determination (FAD) recommends that:

1.1Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:

· who have had at least 1 prior therapy or